FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  O'Keeffe Charles B					2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC.									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>O Reel</u>	ie Charle	<u>S D</u>			$1_{\Gamma}$	CPRX	71							X	Directo	or		10% Ow	ner	
(Last)	(F	irst)	(Middle)		Ĺ	B. Date of Earliest Transaction (Month/Day/Year)									Officer below)	(give title	(give title Other (s		pecify	
355 ALHAMBRA CIRCLE, SUITE 1250						08/25/2015														
(Street)					4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
GABLES	S FI		33134											X		Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City)	(S	tate)	(Zip)												. 0.00					
		Tab	le I - Non	-Deriv	ative	e Se	curit	ies Ac	quired,	Dis	osed o	f, or Be	nefici	ally	Owned					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Dispose Code (Instr. 5)			ities Acquir d Of (D) (Ins		and Securitie Benefici		es Fo ally (D) Following (I)		rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) o	r Pric	e	Transact (Instr. 3	ion(s)			instr. 4)	
Common stock, par value \$0.001 per share 08/25/2					5/201	15			М		30,00	00 A \$		.09	352,126			D		
		7	Fable II - [									or Bend ble secu			wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	Code (					6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S	Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisal		expiration pate	Title	Amou or Numb of Share	er						
Options to purchase common	\$1.09	08/25/2015			M			30,000	11/05/201	.0 1	1/05/2015	Common Stock	30,00	00	\$0	130,00	0	D		

**Explanation of Responses:** 

/s/ Charles B. O'Keeffe

08/26/2015

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.